Luspatercept demonstrates superiority to epoetin-α in ESA-naïve patients with transfusion-dependent low-risk MDS: Interim analysis of the COMMANDS trial

The impact of PET scan-guided de-escalation strategies on 3-year IDFS in HER2+ EBC patients

Addition of olaparib and durvalumab to current SOC may improve PFS in patients with advanced OC without BRCA1/2 mutation

Abemaciclib + ET shows consistent treatment benefits for high-risk EBC patients across all age groups: Subgroup analysis of the monarchE trial

Confirmed OS benefits of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA NSCLC patients: The ADAURA trial

Dostarlimab + carboplatin/paclitaxel shows consistent survival benefits in patients with primary advanced/recurrent EC: The BICR outcomes of the RUBY trial

Erdafitinib demonstrates OS benefits in mUC patients with prior anti-PD-1/PD-L1 therapy: The phase 3 THOR trial

Cilta-cel in earlier lines improves outcomes over SoC in LEN-refractory MM patients